Eli Lilly obesity pill beats Novo Nordisk drug in diabetes trial
A sign with the company logo is sitting outside the center of Eli Lilly in Indiana, Indiana, Indiana on 17 March 2024.
Scott Olson | Getty Images
Hand Lilly He said that the experimental pill performs better on Wednesday Novo NordiskIn the first head -to -head study comparing two drugs in patients with type 2 diabetes, his own oral medicine.
Late-stage work comes closer to being an alternative to another needle in the market that breaks box office records for GLP-1s without Lilly’s pill, dietary restrictions. However, since there is no data comparing the pill of Eli Lillly with the pill of a higher Novo Nordisk in obesity patients, it can be too early to create a clear winner in the pill field.
Eli Lilly said that the pill is superior to lowering blood sugar levels in 52 weeks compared to the oral semagluid of Novo Nordisk. The highest dose of the highest oriental dose of Hemoglobin A1C, a measure of blood sugar levels, helped to decrease to 2.2% compared to 1.4% with Novo Nordisk’s pill.
The highest dose of Eli Lilly’s medication, patients’ pills of Novo Nordisk’s pill, 5.3% loss or 11 pounds compared to 11 pounds of patients to lose an average of 9.2% or 19.7 pounds. Regardless of the shortening, while the weight loss of Orborglpron was 8.2%, while Oral Semagludide was 5.3%.
The results suggest that one hand up to 36 million Lilly pills may be more effective than 14 million oral semaglidids approved under the name of Rybelsus for type 2 diabetes in the treatment of diabetes patients.
“For the majority of patients, this may be the main medicine they need to control their type 2 diabetes and obesity,” Eli Lilly Chief Scientific Responsible. He said.
Nyu Langone Dr. Diabetes & Endocrin Associates is an endocrinologist. Michael Weintraub said that “Blood sugar levels management of Orborglpron is very impressive than all type 2 diabetes drugs, including not only compared to other oral type 2 diabetes drugs, but also injecables.”
The company said that on Wednesday, in 2026, he expected the approved of Orborglpron for the treatment of Type 2 diabetes. Eli Lilly told CEO David Ricks to CNBC in the early August CNBC, hoping to start the “pill” this time this time “next year.
Eli Lilly and Novo Nordisk are competing for a larger part of the market that explodes for the GLP-1s, which some analysts say it would be worth $ 100 billion until the 2030s. The area is willing to ease the supply deficiencies and access barriers created by expensive weekly injections that are dominant at the moment.
According to some analyst estimates, Oral GLP-1s may grow at a value of 50 billion dollars of this total.
Limits of the study
However, how Lilly’s pill is compared with higher doses of oral semaaglutide, especially in patients with overweight or non -diabetal obesity. Novo Nordisk expects US regulators to approve a higher 25 milligrams of dose for obesity treatment by the end of the year, and also examined 50 million doses of the drug in the third stage attempt.
Weintraub said that Eli Lilly’s 36 milligrams of dose of 36 milligrams were compared with Oral Semaglidid at a lower dose than what could be approved in the future. Patients with diabetes lose less weight than those who have no typical condition, so In a study on Type 2 Diabetes patients, oral semagludidine in people with obesity is close to 15%.
The trial shows that Eli Lilly’s pill is better in reducing blood sugar and weight only compared to specific oral Semaglidid doses, “there are a few orders that we look at the results and slowly slow the roll when we get excited.”
Germandoz said it was a little early to say that it was a kind of leader in the drug class.
Detailed results in the essay will be presented at a medical meeting and published in a refereed journal.
Skovronsky said the company cannot work on drugs from competitors that have not yet been approved. However, Eli Lilly said that Lilly was sure that the pill of the pill could be eaten at higher doses of oral Semagludid in head -to -head trials.
Skovronsky likened the effectiveness of the “new generation” injectable GLP-1s of Orborglpron. Eli Lilly refers to Mounjaro and Novo Nordisk’s rival Shot Ozempic.
In the meantime, Skovronsky, Oral Semaglididine “Victoza and Trulity, respectively Novo Nordisk and Eli Lilly’den old diabetes injections, such as the first generation GLP-1s performance performance,” he said.
Rybelsus has been on the market for years, that is, Eli Lilly’s pill will be a late competitor in the field of diabetes. However, both companies are competing to improve oral GLP-1 for obesity.
Unlike Novo Nordisk’s oral semagluid, Eli Lilly’s pill is not a peptide medication. It is a small molecular drug that is more easily absorbed by the body and does not require dietary restrictions.
Trial Details
Eli Lilly’s 3 trials, although an old diabetes drug called Metformin Type 2 diabetes watched about 1,700 adults without well managed well.
The data about the safety of Orborglpron and how much patients tolerate the drug were consistent with previous studies. The most common side effects were gastrointestinal and moderately moderate to moderate.
Eli Lilly said that 9.7% of patients at the highest dose of their pills stopped treatment due to side effects in the study. This is compared to 4.9% of the participants at the highest dose of Novo Nordisk’s drug.
However, Eli Lilly said that the study was not designed to compare the safety and tolerable of two drugs.
Germandoz said that the safety and tolerability of Orborglpron was nothing but the realm of what he expects from the GLP-1s “.
He said, “According to Semagluid, I don’t think we’ve seen any signal about orum,” he said.
Skovronsky, the company is “satisfied” tolerability “and consistent with the GLP-1 injections, he said.
In the meantime, Weintraub said, “It absolutely pauses me,” he said, “seeing a cutting rate because of the side effects of Novo Nordsk’s pill” almost twice “. Eli Lilly’s pill shows a similar rate in the previous late stage attempts, so gastrointestinal side effects were “probably something we need to pay attention to patients and consult the patients.”
